Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL-36: bempegaldesleukin + pembrolizumab versus pembrolizumab in first-line PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
MOH_2021-12-08_010452Phase 3Not yet recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Bempegaldesleukin + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: Not reported. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
bempegaldesleukinpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2021-12-08_010452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-08_010452.